Exemed to buy UCB facility in Vapi, India

Published: 27-Nov-2012
Ingredients Finance

Deal includes multi-year supply agreement between the two companies


India-based Exemed Pharmaceuticals, a manufacturer of active pharmaceutical ingredients, is to buy UCB’s production facility in Vapi, Gujarat, India, for an undisclosed sum.

The transaction, which is in line with UCB’s strategy to focus on bringing new drugs to patients and less on mass manufacturing, includes a multi-year supply agreement between UCB and Exemed. Approximately 80 members of staff will transfer from UCB Vapi to Exemed.

The Vapi plant currently focuses on the production, packaging and distribution of some of UCB mature drugs mainly for the Indian market; it produces around 2% of total UCB volumes.

Exemed Pharmaceuticals will continue with these activities and also plans to bring new business to the site.

  • Companies:
  • UCB
See more

You may also like

Ingredients

Therapeutic: rozanolixizumab for generalised myasthenia gravis

Read more
Generalised myasthenia gravis (gMG) is a rare disease with symptoms that include severe muscular weakness and which is characterised by dysfunction and damage at the neuromuscular junction

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Therapeutic: rozanolixizumab for generalised myasthenia gravis

Generalised myasthenia gravis (gMG) is a rare disease with symptoms that include severe muscular weakness and which is characterised by dysfunction and damage at the neuromuscular junction
Ingredients

Therapeutic: zilucoplan for myasthenia gravis

The rare disease myasthenia gravis (MG) is an autoimmune condition that causes muscle weakness, particularly of those in the face, eyes and that control swallowing
Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes
Ingredients

Therapeutics: dapirolizumab for systemic lupus erythematosus

Although there have been some advances in recent years, systemic lupus erythematosus (SLE) remains a significant unmet medical need
Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Manufacturing

CPI-led UK biotech consortium secures £6.2m of government investment

Project aims to reduce the time it takes to bring biologics to market
Subscribe now